Literature DB >> 18837006

Metabolism of a sulfur-containing heteroarotionoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry.

Zhongfa Liu1, Yilong Zhang, Yousheng Frank Hua, Joseph M Covey, Doris M Benbrook, Kenneth K Chan.   

Abstract

SHetA2 {[(4-nitrophenyl)amino][2,2,4,4-tetramethylthiochroman-6-yl)amino]methanethione], NSC 726189}, a sulfur-containing heteroarotinoid, selectively inhibits cancer cell growth and induces apoptosis without activation of nuclear retinoic acid receptors (RARs). The objective of this study was to investigate its in vitro metabolism in rat and human liver microsomes and in vivo metabolism in the mouse and rat using liquid chromatography-ultraviolet/multi-stage mass spectrometry (LC-UV/MS(n)) on an ion-trap mass spectrometer coupled with a photo-diode array (PDA) detector. In vitro, in the absence of glutathione (GSH), oxidation of the four aliphatic methyl groups of SHetA2 yielded one mono-, two di-, and one tri-hydroxylated SHetA2 metabolites, which were identified based on their UV and multi-stage mass spectra. In the presence of GSH, in addition to these primary oxidative metabolites, four GSH adducts of SHetA2 and a novel rare form thioether GSH adduct was detected and characterized. In vivo, the monohydroxylated SHetA2 metabolites were also detected in mouse and rat plasma and two GSH adducts were detected in rat liver following intravenous (i.v.) bolus administration of SHetA2 at 40 mg/kg.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837006     DOI: 10.1002/rcm.3744

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  13 in total

1.  Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.

Authors:  Satish K Ramraj; Sugantha P Elayapillai; Richard C Pelikan; Yan D Zhao; Zitha R Isingizwe; Amy L Kennedy; Stanley A Lightfoot; Doris M Benbrook
Journal:  Int J Cancer       Date:  2020-01-08       Impact factor: 7.396

2.  Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity.

Authors:  Doris Mangiaracina Benbrook; Suresh Guruswamy; Yuhong Wang; Zhongjie Sun; Altaf Mohammed; Yuting Zhang; Qian Li; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2013-07-12

3.  Development of flexible-heteroarotinoids for kidney cancer.

Authors:  Tongzu Liu; Chioniso Patience Masamha; Shylet Chengedza; K Darrell Berlin; Stan Lightfoot; Feng He; Doris Mangiaracina Benbrook
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

4.  Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice.

Authors:  Ankur Sharma; Mengjie Li; Elangovan Thavathiru; Mariam Ibrahim; Lucila Garcia-Contreras; Doris M Benbrook; Sukyung Woo
Journal:  AAPS J       Date:  2020-02-21       Impact factor: 4.009

5.  NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis.

Authors:  Shylet Chengedza; Doris Mangiaracina Benbrook
Journal:  Anticancer Drugs       Date:  2010-03       Impact factor: 2.248

6.  SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres.

Authors:  Doris Mangiaracina Benbrook; Baskar Nammalwar; Andrew Long; Hiroyuki Matsumoto; Anil Singh; Richard A Bunce; K Darrell Berlin
Journal:  Invest New Drugs       Date:  2013-11-20       Impact factor: 3.850

7.  Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention.

Authors:  Doris M Benbrook; Stan Lightfoot; James Ranger-Moore; Tongzu Liu; Shylet Chengedza; William L Berry; Igor Dozmorov
Journal:  Gene Regul Syst Bio       Date:  2008

8.  Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer.

Authors:  Vishal Chandra; Rajani Rai; Doris Mangiaracina Benbrook
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

9.  Characterization of metabolites of leonurine (SCM-198) in rats after oral administration by liquid chromatography/tandem mass spectrometry and NMR spectrometry.

Authors:  Qing Zhu; Jinlian Zhang; Ping Yang; Bo Tan; Xinhua Liu; Yuanting Zheng; Weimin Cai; Yizhun Zhu
Journal:  ScientificWorldJournal       Date:  2014-02-24

10.  Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2.

Authors:  Ankur Sharma; Doris Mangiaracina Benbrook; Sukyung Woo
Journal:  PLoS One       Date:  2018-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.